Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) traded down 2.8% during mid-day trading on Monday . The stock traded as low as $6.85 and last traded at $7.25. 936,400 shares changed hands during trading, an increase of 15% from the average session volume of 811,531 shares. The stock had previously closed at $7.05.

Several analysts recently issued reports on the stock. Noble Financial reiterated a “buy” rating and set a $16.00 price target on shares of Corbus Pharmaceuticals Holdings in a research report on Friday, September 29th. Cantor Fitzgerald reiterated a “buy” rating and set a $24.00 price target on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, September 20th. ValuEngine lowered shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Finally, BidaskClub upgraded shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $20.75.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals Holdings had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. The business had revenue of $0.80 million for the quarter. equities research analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -0.63 earnings per share for the current fiscal year.

In related news, Director David P. Hochman bought 5,000 shares of the business’s stock in a transaction on Monday, November 13th. The shares were purchased at an average price of $6.90 per share, for a total transaction of $34,500.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David P. Hochman bought 10,000 shares of the business’s stock in a transaction on Friday, November 10th. The stock was bought at an average price of $7.08 per share, for a total transaction of $70,800.00. Following the transaction, the director now directly owns 459,500 shares of the company’s stock, valued at $3,253,260. The disclosure for this purchase can be found here. Insiders acquired 20,336 shares of company stock worth $142,882 in the last 90 days. Company insiders own 11.90% of the company’s stock.

A number of institutional investors have recently modified their holdings of CRBP. State Street Corp boosted its position in Corbus Pharmaceuticals Holdings by 2,998.2% in the second quarter. State Street Corp now owns 588,662 shares of the biopharmaceutical company’s stock valued at $3,708,000 after buying an additional 569,662 shares in the last quarter. Northern Trust Corp boosted its position in Corbus Pharmaceuticals Holdings by 814.3% in the second quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock valued at $3,039,000 after buying an additional 429,584 shares in the last quarter. Vanguard Group Inc. boosted its position in Corbus Pharmaceuticals Holdings by 24.5% in the second quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock valued at $9,850,000 after buying an additional 307,979 shares in the last quarter. Artal Group S.A. acquired a new stake in Corbus Pharmaceuticals Holdings in the second quarter valued at approximately $1,575,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in Corbus Pharmaceuticals Holdings in the second quarter valued at approximately $760,000. Hedge funds and other institutional investors own 29.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/16/corbus-pharmaceuticals-holdings-inc-crbp-stock-price-down-2-8.html.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.